Publication
A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer.
Jenny Högström, Hanna M Doh, Aidan Kump, Boryana Petrova, Peng Wang, Jonathan D Lee, Kaisa Koivula, Nina Kozlova, Kayla A Cruz, Su Min Hong, Camila Perea, Arjun Garg, Michal Weitman, Conor L Evans, Jonathan L Coloff, Jaymin M Patel, Gerburg M Wulf, Laura C Collins, Naama Kanarek, Taru Muranen
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Resistance to standard-of-care therapies remains a major clinical challenge in the treatment of the most common breast cancer, the hormone receptor-positive (HR+) subtype. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in early-stage HR+ disease, yet many patients relapse.…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available